
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

Emergent BioSolutions Inc.

(Name of Registrant as Specified in its Charter)

Not applicable.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

Your **Vote** Counts!

EMERGENT BIOSOLUTIONS INC.

2024 Annual Meeting
Vote by May 22, 2024
11:59 PM ET

EMERGENT BIOSOLUTIONS INC.
300 PROFESSIONAL DRIVE
GATHERSBURG, MD 20879



V45248-P06298

You invested in EMERGENT BIOSOLUTIONS INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 23, 2024.**

Get informed before you vote

View the Notice of the Meeting, Annual Report on Form 10-K, Proxy Statement and Proxy Card online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 9, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and
vote without entering a
control number



Vote Virtually at the Meeting*

May 23, 2024
9:00 a.m. Eastern Time

Virtually at:
www.virtualshareholdermeeting.com/EBS2024

*Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items	Board Recommends
1. To elect three Class III directors to hold office for a term expiring at our 2027 Annual Meeting of Stockholders, each to serve and until their respective successors are duly elected and qualified;	
Nominees Class III:	
1a. Donald DeGolyer	✔ For
1b. Neal Fowler	✔ For
1c. Marvin White	✔ For
2. To ratify the appointment by the audit and finance committee of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;	✔ For
3. To hold, on an advisory basis, a vote to approve the 2023 compensation of our named executive officers;	✔ For
4. To approve an amendment to the Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan.	✔ For
Other business may be considered as may properly come before the meeting or any adjournment or postponement of the meeting.	

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".